Remus Pharmaceuticals Limited — PPTs, 19-05-2025: Investor Presentation

1. Financial Highlights:

Remus Pharmaceuticals reported consolidated revenue of ₹620 Cr in FY25, up from ₹213 Cr in FY24. EBITDA grew to ₹50 Cr from ₹32 Cr, with standalone EBITDA margin improving marginally to 36.7%. PAT rose substantially to ₹38 Cr consolidated and ₹20 Cr standalone, indicating solid profitability growth. The balance sheet remains healthy with equity reserves at ₹256 Cr and minimal net debt. Return ratios are strong, with ROCE at 15% and ROE near 16%. Diluted EPS consolidated improved sharply to ₹65.2.

2. Strategic Initiatives & Growth Drivers:

The company is aggressively expanding across semi-regulated and regulated markets including Latin America, CIS, Africa, Southeast Asia, Mexico, and Eastern Europe. It plans to file 2000 new product dossiers over three years focused on niche and complex formulations. Investments continue in trademark registrations, regulatory compliance, and strengthening commercialization via direct-to-consumer and pharmacy channels.

3. Business Developments:

Recent progress includes launching over 10 off-patent niche products and expanding product filings in Bosnia, Mexico, and Saudi Arabia. New product rollouts in Bolivia’s private market are backed by partnerships with pharmacy chains and hospitals. The acquisition of Espee USA enhances clinical trial and biotech services. Subsidiary growth extends across Bolivia, Guatemala, Ecuador, and other LATAM countries.

4. Market Position & Competitive Advantage:

With over 620 registered products, Remus holds leadership in specialty and niche pharma. A strong regulatory affairs team accelerates market entry, securing first-mover advantages in semi-regulated markets. Brand building through Relius and robust quality standards strengthen its competitive moat and scale in emerging pharma markets.

5. Investor Implications:

Focused portfolio growth and geographic diversification support positive growth potential. Margin improvement and brand investments create sustainable value drivers. Execution risks include regulatory challenges and subsidiary integration but rising revenues and strong returns position the company well for future expansion.